The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk

Cancer Lett. 2007 Jan 8;245(1-2):61-8. doi: 10.1016/j.canlet.2005.12.026. Epub 2006 Feb 3.

Abstract

We evaluated the association between the XPD exon 10 Asp(312)Asn and exon 23 Lys(751)Gln polymorphisms and the risk of pancreatic cancer in a hospital-based study of 344 patients and 386 controls frequency matched by age, gender, and race. Stratified analyses showed ever smokers carrying the Asn(312)Asn genotype had a significantly reduced risk when compared with those carrying the (312)Asp allele (OR=0.46, 95% confidence interval 0.24-0.88) (P for interaction=0.03). The (312)Asp-(751)Gln was identified as the putative at risk haplotype. Our study shows that the XPD gene polymorphism could be a genetic risk modifier for smoking-related pancreatic cancer.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenocarcinoma / etiology
  • Adenocarcinoma / genetics
  • Adenocarcinoma / pathology
  • Aged
  • Amino Acid Substitution
  • Asparagine / genetics
  • Aspartic Acid / genetics
  • Carcinoma, Pancreatic Ductal / etiology
  • Carcinoma, Pancreatic Ductal / genetics
  • Carcinoma, Pancreatic Ductal / pathology
  • Case-Control Studies
  • Female
  • Gene Frequency
  • Genotype
  • Glutamine / genetics
  • Haplotypes*
  • Humans
  • Linkage Disequilibrium
  • Lysine / genetics
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / etiology
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / pathology
  • Polymorphism, Single Nucleotide*
  • Risk Factors
  • Smoking / adverse effects
  • Xeroderma Pigmentosum Group D Protein / genetics*

Substances

  • Glutamine
  • Aspartic Acid
  • Asparagine
  • Xeroderma Pigmentosum Group D Protein
  • Lysine